HemoPill for Upper GI Bleeding

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
NYU Langone Health, New York, NY
Upper GI Bleeding+1 More
HemoPill - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new pill that has a built in sensor to detect if there is bleeding in the upper digestive tract. The information from the sensor is then transmitted to medical personnel. HemoPill is used to treat Upper GI Bleeding and has been previously approved by the FDA for a different condition. No patients in this trial will receive a placebo.

Eligible Conditions

  • Upper GI Bleeding

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 1 hour after endoscopy procedure

Hour 1
Number of False negative results
Number of False positive results
Number of True negative results
Number of True positive results

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

HemoPIll group
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: HemoPill · No Placebo Group · N/A

HemoPIll group
Device
Experimental Group · 1 Intervention: HemoPill · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 hour after endoscopy procedure
Closest Location: NYU Langone Health · New York, NY
Photo of NYU Langone Health 1Photo of NYU Langone Health 2Photo of NYU Langone Health 3
2020First Recorded Clinical Trial
1 TrialsResearching Upper GI Bleeding
110 CompletedClinical Trials

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,236 Previous Clinical Trials
749,969 Total Patients Enrolled
Melissa Latorre, MDPrincipal InvestigatorNYU Langone Health

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are scheduled for endoscopy due to suspicion of UGIB based on clinical and / or laboratory findings.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.